Literature DB >> 22526674

The A subunit of Escherichia coli heat-labile enterotoxin functions as a mucosal adjuvant and promotes IgG2a, IgA, and Th17 responses to vaccine antigens.

Elizabeth B Norton1, Louise B Lawson, Zaid Mahdi, Lucy C Freytag, John D Clements.   

Abstract

Enterotoxigenic Escherichia coli (ETEC) produces both heat-labile (LT) and heat-stable (ST) enterotoxins and is a major cause of diarrhea in infants in developing countries and in travelers to those regions. In addition to inducing fluid secretion, LT is a powerful mucosal adjuvant capable of promoting immune responses to coadministered antigens. In this study, we examined purified A subunit to further understand the toxicity and adjuvanticity of LT. Purified A subunit was enzymatically active but sensitive to proteolytic degradation and unable to bind gangliosides, and even in the presence of admixed B subunit, it displayed low cyclic AMP (cAMP) induction and no enterotoxicity. Thus, the AB5 structure plays a key role in protecting the A subunit from proteolytic degradation and in delivering the enzymatic signals required for secretion. In contrast, the A subunit alone was capable of activating dendritic cells and enhanced immune responses to multiple antigens following intranasal immunization; therefore, unlike toxicity, LT adjuvanticity is not dependent on the AB5 holotoxin structure or the presence of the B subunit. However, immune responses were maximal when signals were received from both subunits either in an AB5 structure or with A and B admixed. Furthermore, the quality of the immune response (i.e., IgG1/IgG2 balance and mucosal IgA and IL-17 secretion) was determined by the presence of an A subunit, revealing for the first time induction of Th17 responses with the A subunit alone. These results have important implications for understanding ETEC pathogenesis, unraveling immunologic responses induced by LT-based adjuvants, and developing new mucosal vaccines.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22526674      PMCID: PMC3416479          DOI: 10.1128/IAI.00181-12

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  60 in total

Review 1.  Mucosal delivery routes for optimal immunization: targeting immunity to the right tissues.

Authors:  C Czerkinsky; J Holmgren
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

2.  Mutations in the A subunit affect yield, stability, and protease sensitivity of nontoxic derivatives of heat-labile enterotoxin.

Authors:  C Magagnoli; R Manetti; M R Fontana; V Giannelli; M M Giuliani; R Rappuoli; M Pizza
Journal:  Infect Immun       Date:  1996-12       Impact factor: 3.441

3.  Comparison of the tissue receptors for Vibrio cholerae and Escherichia coli enterotoxins by means of gangliosides and natural cholera toxoid.

Authors:  J Holmgren
Journal:  Infect Immun       Date:  1973-12       Impact factor: 3.441

4.  Cutting edge: lung mucosal Th17-mediated responses induce polymeric Ig receptor expression by the airway epithelium and elevate secretory IgA levels.

Authors:  Zeina Jaffar; Maria E Ferrini; Lou A Herritt; Kevan Roberts
Journal:  J Immunol       Date:  2009-04-15       Impact factor: 5.422

5.  cAMP-independent effects of cholera toxin on B cell activation. III. Cholera toxin A subunit-mediated ADP-ribosylation acts synergistically with ionomycin or IL-4 to induce B cell proliferation.

Authors:  M L Francis; I Okazaki; J Moss; A Kurosky; L M Pecanha; J J Mond
Journal:  J Immunol       Date:  1995-05-15       Impact factor: 5.422

6.  Escherichia coli heat-labile enterotoxin promotes protective Th17 responses against infection by driving innate IL-1 and IL-23 production.

Authors:  Corinna F Brereton; Caroline E Sutton; Pádraig J Ross; Yoichiro Iwakura; Mariagrazia Pizza; Rino Rappuoli; Ed C Lavelle; Kingston H G Mills
Journal:  J Immunol       Date:  2011-04-13       Impact factor: 5.422

7.  Toward the development of a stable, freeze-dried formulation of Helicobacter pylori killed whole cell vaccine adjuvanted with a novel mutant of Escherichia coli heat-labile toxin.

Authors:  Nancy A Summerton; Richard W Welch; Laureano Bondoc; Huei-Hsiung Yang; Brett Pleune; Naryaswamy Ramachandran; Andrea M Harris; Desiree Bland; W James Jackson; Sukjoon Park; John D Clements; Gary S Nabors
Journal:  Vaccine       Date:  2009-11-06       Impact factor: 3.641

8.  Cholera toxin and Escherichia coli heat-labile enterotoxin, but not their nontoxic counterparts, improve the antigen-presenting cell function of human B lymphocytes.

Authors:  Donatella R M Negri; Dora Pinto; Silvia Vendetti; Mario Patrizio; Massimo Sanchez; Antonella Riccomi; Paolo Ruggiero; Giuseppe Del Giudice; Maria Teresa De Magistris
Journal:  Infect Immun       Date:  2009-02-17       Impact factor: 3.441

9.  Construction of a potential live oral bivalent vaccine for typhoid fever and cholera-Escherichia coli-related diarrheas.

Authors:  J D Clements; S El-Morshidy
Journal:  Infect Immun       Date:  1984-11       Impact factor: 3.441

10.  Dissociation of Escherichia coli heat-labile enterotoxin adjuvanticity from ADP-ribosyltransferase activity.

Authors:  B L Dickinson; J D Clements
Journal:  Infect Immun       Date:  1995-05       Impact factor: 3.441

View more
  33 in total

1.  Intradermal or Sublingual Delivery and Heat-Labile Enterotoxin Proteins Shape Immunologic Responses to a CFA/I Fimbria-Derived Subunit Antigen Vaccine against Enterotoxigenic Escherichia coli.

Authors:  Milton Maciel; David Bauer; Robin L Baudier; Jacob Bitoun; John D Clements; Steven T Poole; Mark A Smith; Robert W Kaminski; Stephen J Savarino; Elizabeth B Norton
Journal:  Infect Immun       Date:  2019-10-18       Impact factor: 3.441

2.  Immunological considerations in the development of Pseudomonas aeruginosa vaccines.

Authors:  Sarah M Baker; James B McLachlan; Lisa A Morici
Journal:  Hum Vaccin Immunother       Date:  2019-09-05       Impact factor: 3.452

3.  A double mutant heat-labile toxin from Escherichia coli, LT(R192G/L211A), is an effective mucosal adjuvant for vaccination against Helicobacter pylori infection.

Authors:  Louise Sjökvist Ottsjö; Carl-Fredrik Flach; John Clements; Jan Holmgren; Sukanya Raghavan
Journal:  Infect Immun       Date:  2013-02-25       Impact factor: 3.441

4.  Oral Biologic Delivery: Advances Toward Oral Subunit, DNA, and mRNA Vaccines and the Potential for Mass Vaccination During Pandemics.

Authors:  Jacob William Coffey; Gaurav Das Gaiha; Giovanni Traverso
Journal:  Annu Rev Pharmacol Toxicol       Date:  2020-08-31       Impact factor: 13.820

5.  Characterization of a novel fusion protein from IpaB and IpaD of Shigella spp. and its potential as a pan-Shigella vaccine.

Authors:  Francisco J Martinez-Becerra; Xiaotong Chen; Nicholas E Dickenson; Shyamal P Choudhari; Kelly Harrison; John D Clements; William D Picking; Lillian L Van De Verg; Richard I Walker; Wendy L Picking
Journal:  Infect Immun       Date:  2013-09-23       Impact factor: 3.441

6.  Fentanyl conjugate vaccine by injected or mucosal delivery with dmLT or LTA1 adjuvants implicates IgA in protection from drug challenge.

Authors:  Addison E Stone; Sarah E Scheuermann; Colin N Haile; Gregory D Cuny; Marcela Lopez Velasquez; Joshua P Linhuber; Anantha L Duddupudi; Jennifer R Vigliaturo; Marco Pravetoni; Therese A Kosten; Thomas R Kosten; Elizabeth B Norton
Journal:  NPJ Vaccines       Date:  2021-05-13       Impact factor: 7.344

7.  Simultaneous exposure to Escherichia coli heat-labile and heat-stable enterotoxins increases fluid secretion and alters cyclic nucleotide and cytokine production by intestinal epithelial cells.

Authors:  Lisa T Read; Rachel W Hahn; Carli C Thompson; David L Bauer; Elizabeth B Norton; John D Clements
Journal:  Infect Immun       Date:  2014-10-06       Impact factor: 3.441

8.  dmLT Adjuvant Enhances Cytokine Responses to T Cell Stimuli, Whole Cell Vaccine Antigens and Lipopolysaccharide in Both Adults and Infants.

Authors:  Marjahan Akhtar; Nuder Nower Nizam; Salima Raiyan Basher; Lazina Hossain; Sarmin Akter; Taufiqur Rahman Bhuiyan; Firdausi Qadri; Anna Lundgren
Journal:  Front Immunol       Date:  2021-05-14       Impact factor: 7.561

9.  The adjuvant double mutant Escherichia coli heat labile toxin enhances IL-17A production in human T cells specific for bacterial vaccine antigens.

Authors:  Susannah Leach; John D Clements; Joanna Kaim; Anna Lundgren
Journal:  PLoS One       Date:  2012-12-20       Impact factor: 3.240

Review 10.  Pig vaccination strategies based on enterotoxigenic Escherichia coli toxins.

Authors:  J Daniel Dubreuil
Journal:  Braz J Microbiol       Date:  2021-07-10       Impact factor: 2.476

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.